Procter & Gamble stock holds steady as fiscal 2025 sales reached $84.3 billion

Procter & Gamble stock is anchored by fiscal 2025 sales of $84.3 billion and diluted net earnings per share of $6.51, both reported for the year ended 30 June 2025. The company also posted core EPS of $6.83, which was $0.32 above reported diluted EPS, according to Procter & Gamble investor materials.

Fiscal 2025 shows scale

For fiscal 2025, Procter & Gamble said organic sales increased 2% versus the prior year, while reported sales were $84.3 billion. That combination matters because it shows modest top-line expansion even as the group managed a large consumer portfolio across multiple categories.

The same reporting cycle put core profit at $16.0 billion, compared with diluted net earnings of $16.0 billion and diluted EPS of $6.51. The gap between core EPS and reported EPS was $0.32 per share, which is a clean reminder that the company's underlying earnings picture can differ from statutory results.

Margins and cash matter

Procter & Gamble's fiscal 2025 core gross margin was 51.8%, while core operating margin reached 23.5%. Those two figures frame the company more clearly than sales alone, because they show how much of each revenue dollar was retained after input costs and operating expenses.

Free cash flow for fiscal 2025 was $15.9 billion, and the company returned $17.4 billion to shareholders through dividends and share repurchases. In practical terms, cash generation remained strong enough to fund both capital returns and ongoing brand investment.

Guidance stayed constructive

For fiscal 2026, Procter & Gamble guided to organic sales growth of 0% to 4% and core EPS growth of 0% to 4%. That range is important for investors because it implies a year of slower, but still positive, growth relative to the 2% organic sales gain reported for fiscal 2025.

The company also said fiscal 2026 would face a $1.0 billion after-tax headwind from commodity and transportation costs and a roughly $1.5 billion after-tax headwind from foreign exchange. Those two inputs help explain why margin performance, not just revenue, remains central to the stock narrative.

Beauty and grooming

Within the portfolio, Beauty and Grooming remain the most visible consumer-facing engines. In fiscal 2025, Beauty generated $14.5 billion in net sales and Grooming generated $6.5 billion, giving the market a clear view of the categories that carry the brand mix.

Skin and Personal Care added $12.0 billion in net sales, while Health Care contributed $10.3 billion. The spread across categories reduces reliance on any single line, and it helps explain why investors usually focus on volume, pricing, and margin together rather than one product cycle alone.

Stock valuation lens

Without a fresh market quote in the available source set, the most current evidence for Procter & Gamble stock comes from its reported fiscal 2025 results and fiscal 2026 guidance. The company ended the year with a market capitalization of about $365 billion as a widely used reference point around the latest reporting period, underscoring its status as one of the largest consumer staples names.

That scale, combined with $84.3 billion in fiscal 2025 sales and $15.9 billion in free cash flow, keeps the stock framed around defensive earnings quality rather than rapid expansion. For readers tracking the shares, the main question is whether the next year can turn the 0% to 4% organic sales outlook into cleaner margin leverage.